| Abstract | BACKGROUND: The purpose of this study is to evaluate the efficacy of postoperative adjuvant chemotherapy using uracil and tegafur (UFT) for colorectal cancer. METHODS: In a multicenter trial among 43 institutions for patients who underwent curative resection of Dukes' B or C colorectal cancer, a surgery alone group (control group) and a treatment group (UFT group) to which UFT was administered at 400 mg/day for 2 years following surgery were compared. A total of 320 patients were registered between March 1991 and April 1994, and 289 of these patients were analyzed as a full-analysis set. RESULTS: The 5-year disease-free survival rate was 75.7% in the UFT group and 60.1% in the control group, respectively, and the stratified log-rank test showed the statistical significance ( P=0.0081). This difference was marked in rectal cancer ( P=0.0016) and, in particular, the local recurrence was reduced. No significant difference was observed in the 5-year survival rate. The incidence of adverse reactions on administration of UFT was low, and there was no serious adverse reaction. CONCLUSION: It is suggested that the consecutive administration of UFT at 400 mg/day was an effective and highly safe therapeutic method as postoperative adjuvant chemotherapy for rectal cancer. |
| Authors | T Kato, Y Ohashi, H Nakazato, A Koike, S Saji, H Suzuki, H Takagi, Y Nimura, A Hasumi, S Baba, T Manabe, M Maruta, K Miura, A Yamaguchi
(Affiliation: Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.)
|
| Journal | Langenbeck's archives of surgery / Deutsche Gesellschaft für Chirurgie
(Langenbecks Arch Surg)
Vol. 386
Issue 8
Pg. 575-81
(Mar 2002)
ISSN: 1435-2443 Germany |
| PMID | 11914933
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Antineoplastic Agents
- Drug Combinations
- UFT(R) drug
- Tegafur
- Uracil
|
| Topics |
- Adenocarcinoma
(drug therapy, pathology, surgery)
- Administration, Oral
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Chemotherapy, Adjuvant
- Colorectal Neoplasms
(drug therapy, pathology, surgery)
- Disease-Free Survival
- Drug Combinations
- Female
- Humans
- Male
- Middle Aged
- Postoperative Period
- Prospective Studies
- Recurrence
- Survival Rate
- Tegafur
(adverse effects, therapeutic use)
- Treatment Outcome
- Uracil
(adverse effects, therapeutic use)
|
